Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
63
ALPMY Quote, Financials, Valuation and Earnings
Last price:
$13.65
Seasonality move
:
2.58%
Day range:
$13.49 - $13.92
52-week range:
$8.37 - $13.92
Dividend yield:
0%
P/E ratio:
28.39x
P/S ratio:
1.81x
P/B ratio:
2.23x
Volume:
285.6K
Avg. volume:
108.9K
1-year change:
34.72%
Market cap:
$24.3B
Revenue:
$12.5B
EPS (TTM):
$0.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALPMY
Astellas Pharma, Inc.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.35% | -- | $17.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALPMY
Astellas Pharma, Inc.
|
$13.58 | -- | $24.3B | 28.39x | $0.26 | 0% | 1.81x |
|
HLOSF
Healios KK
|
$2.31 | -- | $266.6M | -- | $0.00 | 0% | 362.71x |
|
PPTDF
PeptiDream Inc.
|
$12.19 | -- | $1.6B | 13.79x | $0.00 | 0% | 13.13x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.52 | -- | $499.1M | -- | $0.00 | 0% | 2.58x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.61 | $17.76 | $46.1B | 185.41x | $0.32 | 4.53% | 1.57x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALPMY
Astellas Pharma, Inc.
|
31.47% | 0.008 | 25.73% | 0.75x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALPMY
Astellas Pharma, Inc.
|
$2.6B | $729.9M | 5.2% | 8.36% | 20.53% | $1.4B |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Astellas Pharma, Inc. vs. Competitors
-
Which has Higher Returns ALPMY or HLOSF?
Healios KK has a net margin of 15.11% compared to Astellas Pharma, Inc.'s net margin of -9751.87%. Astellas Pharma, Inc.'s return on equity of 8.36% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital ALPMYAstellas Pharma, Inc.73.63% $0.30 $15.9B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About ALPMY or HLOSF?
Astellas Pharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma, Inc. has higher upside potential than Healios KK, analysts believe Astellas Pharma, Inc. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings ALPMYAstellas Pharma, Inc.0 0 0 HLOSFHealios KK0 0 0 -
Is ALPMY or HLOSF More Risky?
Astellas Pharma, Inc. has a beta of 0.214, which suggesting that the stock is 78.59% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock ALPMY or HLOSF?
Astellas Pharma, Inc. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma, Inc. pays 183.34% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALPMY or HLOSF?
Astellas Pharma, Inc. quarterly revenues are $3.6B, which are larger than Healios KK quarterly revenues of $128.8K. Astellas Pharma, Inc.'s net income of $537.1M is higher than Healios KK's net income of $3.8M. Notably, Astellas Pharma, Inc.'s price-to-earnings ratio is 28.39x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma, Inc. is 1.81x versus 362.71x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALPMYAstellas Pharma, Inc.1.81x 28.39x $3.6B $537.1M HLOSFHealios KK362.71x -- $128.8K $3.8M
-
Which has Higher Returns ALPMY or PPTDF?
PeptiDream Inc. has a net margin of 15.11% compared to Astellas Pharma, Inc.'s net margin of -25.38%. Astellas Pharma, Inc.'s return on equity of 8.36% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital ALPMYAstellas Pharma, Inc.73.63% $0.30 $15.9B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About ALPMY or PPTDF?
Astellas Pharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma, Inc. has higher upside potential than PeptiDream Inc., analysts believe Astellas Pharma, Inc. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALPMYAstellas Pharma, Inc.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is ALPMY or PPTDF More Risky?
Astellas Pharma, Inc. has a beta of 0.214, which suggesting that the stock is 78.59% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock ALPMY or PPTDF?
Astellas Pharma, Inc. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma, Inc. pays 183.34% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALPMY or PPTDF?
Astellas Pharma, Inc. quarterly revenues are $3.6B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Astellas Pharma, Inc.'s net income of $537.1M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Astellas Pharma, Inc.'s price-to-earnings ratio is 28.39x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma, Inc. is 1.81x versus 13.13x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALPMYAstellas Pharma, Inc.1.81x 28.39x $3.6B $537.1M PPTDFPeptiDream Inc.13.13x 13.79x $29.3M -$7.4M
-
Which has Higher Returns ALPMY or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 15.11% compared to Astellas Pharma, Inc.'s net margin of -24.76%. Astellas Pharma, Inc.'s return on equity of 8.36% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital ALPMYAstellas Pharma, Inc.73.63% $0.30 $15.9B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About ALPMY or SOLTF?
Astellas Pharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma, Inc. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Astellas Pharma, Inc. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ALPMYAstellas Pharma, Inc.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is ALPMY or SOLTF More Risky?
Astellas Pharma, Inc. has a beta of 0.214, which suggesting that the stock is 78.59% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock ALPMY or SOLTF?
Astellas Pharma, Inc. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma, Inc. pays 183.34% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALPMY or SOLTF?
Astellas Pharma, Inc. quarterly revenues are $3.6B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Astellas Pharma, Inc.'s net income of $537.1M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Astellas Pharma, Inc.'s price-to-earnings ratio is 28.39x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma, Inc. is 1.81x versus 2.58x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALPMYAstellas Pharma, Inc.1.81x 28.39x $3.6B $537.1M SOLTFNxera Pharma Co., Ltd.2.58x -- $45.8M -$11.3M
-
Which has Higher Returns ALPMY or STMM?
Stemcell Holdings, Inc. has a net margin of 15.11% compared to Astellas Pharma, Inc.'s net margin of --. Astellas Pharma, Inc.'s return on equity of 8.36% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALPMYAstellas Pharma, Inc.73.63% $0.30 $15.9B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About ALPMY or STMM?
Astellas Pharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma, Inc. has higher upside potential than Stemcell Holdings, Inc., analysts believe Astellas Pharma, Inc. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALPMYAstellas Pharma, Inc.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is ALPMY or STMM More Risky?
Astellas Pharma, Inc. has a beta of 0.214, which suggesting that the stock is 78.59% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ALPMY or STMM?
Astellas Pharma, Inc. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma, Inc. pays 183.34% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALPMY or STMM?
Astellas Pharma, Inc. quarterly revenues are $3.6B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Astellas Pharma, Inc.'s net income of $537.1M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Astellas Pharma, Inc.'s price-to-earnings ratio is 28.39x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma, Inc. is 1.81x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALPMYAstellas Pharma, Inc.1.81x 28.39x $3.6B $537.1M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns ALPMY or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 15.11% compared to Astellas Pharma, Inc.'s net margin of -1.05%. Astellas Pharma, Inc.'s return on equity of 8.36% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital ALPMYAstellas Pharma, Inc.73.63% $0.30 $15.9B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About ALPMY or TAK?
Astellas Pharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 21.36%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Astellas Pharma, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Astellas Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALPMYAstellas Pharma, Inc.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is ALPMY or TAK More Risky?
Astellas Pharma, Inc. has a beta of 0.214, which suggesting that the stock is 78.59% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock ALPMY or TAK?
Astellas Pharma, Inc. has a quarterly dividend of $0.26 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.53% to investors and pays a quarterly dividend of $0.32 per share. Astellas Pharma, Inc. pays 183.34% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALPMY or TAK?
Astellas Pharma, Inc. quarterly revenues are $3.6B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Astellas Pharma, Inc.'s net income of $537.1M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Astellas Pharma, Inc.'s price-to-earnings ratio is 28.39x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 185.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma, Inc. is 1.81x versus 1.57x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALPMYAstellas Pharma, Inc.1.81x 28.39x $3.6B $537.1M TAKTakeda Pharmaceutical Co., Ltd.1.57x 185.41x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is up 3.92% over the past day.
